NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.390) was uploaded to the NHS England Website on Tuesday 24, March 2026.
The following changes have been introduced:
Pembrolizumab (PEMB34)
Pembrolizumab for resectable, locally advanced, head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)
Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Moved into routine commissioning - section B of list
NA (DOS3)
NA
Moved into routine commissioning - section B of list
Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Moved into routine commissioning - section B of list
Obecabtagene autoleucel (OBE01a)
Obecabtagene autoleucel (obecel) CAR-T cells for treating relapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (OBE01b) can only be completed as a continuation of this first part of the form (OBE01a) and OBE01b must be completed on infusion CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of obecabtagene autoleucel (obecel). Note: the second part of the form (OBE01b) will only appear after the above first part of the form (OBE01a) has been fully completed and submitted. To complete the second part of the form, the user will have to complete a continuation request for the OBE1a application.
Moved into routine commissioning - section B of list
Talazoparib plus enzalutamide (TAL2)
For the treatment of metastatic hormone- relapsed (castrate-resistant) prostate cancer in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate where the following criteria have been met
Moved into routine commissioning - section B of list
Epcoritamab monotherapy (EPC2)
Epcoritamab monotherapy for previously treated adult patients with relapsed/refractory follicular lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met
Date moving into routine commissioning updated
Lenvatinib with everolimus (LNV1)
The treatment of previously treated advanced renal cell carcinoma
Treatment criterion (#10 and 11) updated; Treatment criteria (#10) removed
Trastuzumab emtansine MONOTHERAPY (TRA2)
As adjuvant therapy for patients with HER2-positive early breast cancer who have residual invasive disease following the combination of taxane-based and HER2-targeted neoadjuvant systemic therapy and surgery where the following criteria have been met
Drug column updated; Treatment criterion (#5 and 10) updated; Treatment criterion (#7 and 11) removed